At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
The vision for WW Scientific Publications is to be strategic leaders driving scientific publications with innovative approaches to advance understanding of the science and maximize value for customers. The position reports to the Team Lead/Director of Early Assets & Biomarkers Worldwide Scientific Publications within Medical Capabilities of Global Medical Affairs and is responsible for the strategy and execution of the BMS Early Assets & Biomarkers portfolio scientific publications worldwide, with particular focus on biomarkers, diagnostics, and translational medicine. The lead of Early Assets & Biomarkers Scientific Publications will ensure the disclosure of the science of BMS products and research data to inform Healthcare Providers and Patients worldwide.
Key Responsibilities
A core member of Worldwide Early Assets & Biomarkers Scientific Publications Team, the Associate Director for Early Assets & Biomarkers, with a focus on biomarkers, diagnostics, and translational medicine, is accountable for:
* Manages across a global matrix organization to drive quality planning and timely communication of key scientific and clinical information for BMS products within specified therapeutic area
* Drives strategic publication planning and provides oversight for publication strategy of assigned therapeutic area and assets
* Builds strong cross-functional collaborations and ensures alignment of the scientific communication plan with both the research and business plan for the therapeutic area
* Provides expert scientific guidance and support to cross-functional colleagues, as to positively impact the business broadly and globally
* Demonstrates scientific and functional expertise to support the establishment of strong working collaborations with both internal and external disease-area experts to ensure quality data analysis, interpretation, and communication planning
* Ensures timely publication and global communication of key data at congresses and in high-tier journals that comply with laws, regulations and guidelines
* Directs, reviews, and approves manuscripts, abstracts, posters, and other documents to ensure appropriate evaluation and presentation of data, methodology, and interpretation
* Assists Team Lead/Director by acting as liaison/representing Scientific Publications at intra- and interdepartmental meetings, participating in decisions that impact the overall medical/scientific support of products within the therapeutic and asset teams
* Collaborates and partners with internal stakeholders across the matrix and other Medical Capabilities leadership (eg, Scientific Content, Customer Engagement, Field Medical Excellence, Compliance & Governance) to ensure efficiency and value
* Partners externally with 3rd-party vendors to ensure the appropriate balance of internal and external execution of work
* Manages annual budget and works within allocated resources
* Reinforce good publication practices and principles among authors and internal publication stakeholder community
Qualifications & Experience
* Advance scientific degree, PhD, PharmD or MD preferred
* A minimum of 5 years experience Pharmaceutical/Healthcare industry experience with a focus on scientific publications; experience in oncology, hematology, and/or immunology preferred
* Expertise across all aspects of scientific publication strategy, planning, and execution during all phases of drug development and commercialization process
* Demonstrated track record of leading and executing in highly matrix environment working across multiple functional areas
* Proven ability to think strategically at an enterprise level and lead teams to make strategic decisions even under conditions of ambiguity, evolving landscapes, and tight timelines
* Adept at building credibility with external investigators & collaborative partners, evidenced by strong leadership behaviors and scientific excellence
* Certified Medical Publication Professional (CMPP), and ISMPP active member highly desired
* Outstanding interpersonal, written and verbal communication skills
* Ability to travel (domestically and internationally) approximately 15-20% of the time
Knowledge Desired
* Pharmaceutical/Healthcare Industry
* External compliance, transparency and conflict-of-interest regulated work environments
* Understanding of preclinical data, translational research, clinical trial design and execution, statistical methods, and clinical trial data reporting requirements; ability to analyze and interpret complex preclinical, translational, and clinical information
* In-depth knowledge of Good Publication Practices and guidance (GPP3, ICMJE), Sunshine Act, Pharma Code
of Conduct, and other guidance related to post-marketing practices and scientific data communication
* Working knowledge of Microsoft suite of applications, and familiar with publication management tool
(eg, DataVision)
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.